

Journal of Visualized Experiments

Two-vessel occlusion mouse model of cerebral ischemia–reperfusion

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59078R2
Full Title:	Two-vessel occlusion mouse model of cerebral ischemia–reperfusion
Keywords:	Cerebral ischemia-reperfusion, middle cerebral artery occlusion, 2,3,5-triphenyltetrazolium chloride assay, open field assay, infarct volume, Image J
Corresponding Author:	Gilbert Lee TAIWAN
Corresponding Author's Institution:	
Corresponding Author E-Mail:	154101@h.tmu.edu.tw
Order of Authors:	Cheng-Yu Chen Ray-Jade Chen Gilbert Lee
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Taipei, Taiwan

Dr. Aaron Berard

Science Editor

JoVE

1 Alewife Center | Suite 200 | Cambridge | MA | 02140

Dear Dr. Berard,

We wish to submit a manuscript entitled “Two-vessel occlusion mouse model of cerebral ischemia–reperfusion” to be considered for publication by *JoVE*.

In this study, we establish a mouse model of cerebral ischemia–reperfusion for investigating the pathophysiology of stroke. This middle cerebral artery occlusion model induces a stable infarct size, a bulk of brain-infiltrating immune cells in the ischemic brain, and behavioral deficit after cerebral ischemia–reperfusion.

All authors have read and approved the submitted manuscript, and the manuscript has not been submitted nor published elsewhere in whole or in part.

We respectfully suggest the following individuals as reviewers.

1. Chi-Mei Hsueh, Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
2. Zsuzsanna Fabry, Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.

Please address all correspondence concerning this manuscript to Dr. Gilbert Lee at
154101@h.tmu.edu.tw

Thank you for your consideration of this manuscript.

Yours sincerely,

Gilbert Lee

TITLE:

Two-vessel Occlusion Mouse Model of Cerebral Ischemia–reperfusion

AUTHORS AND AFFILIATIONS:

Cheng-Yu Chen^{1–5,*}, Ray-Jade Chen^{6,7,*}, Gilbert Aaron Lee⁵

¹Research Center of Translational Imaging, College of Medicine, Taipei Medical University, Taipei, Taiwan

²Radiogenomic Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

³Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

⁴Department of Medical Imaging, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

⁵Department of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan

⁶Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

⁷Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan

*These authors contributed equally to this study.

Corresponding author:

Gilbert Aaron Lee (154101@h.tmu.edu.tw)

Email addresses of co-authors:

Cheng-Yu Chen (sandy0932@gmail.com)

Ray-Jade Chen (rayjchen@tmu.edu.tw)

KEYWORDS:

cerebral ischemia–reperfusion, middle cerebral artery occlusion, 2,3,5-triphenyltetrazolium chloride assay, open-field assay, infarct volume, ImageJ

SUMMARY:

A mouse model of cerebral ischemia–reperfusion is established to investigate the pathophysiology of stroke. We distally ligate the right middle cerebral artery and right common carotid artery and restore blood flow after 10 or 40 min of ischemia.

ABSTRACT:

In this study, a middle cerebral artery (MCA) occlusion mouse model is employed to study cerebral ischemia–reperfusion. A reproducible and reliable mouse model is useful for investigating the pathophysiology of cerebral ischemia-reperfusion and determining potential therapeutic strategies for patients with stroke. Variations in the anatomy of the circle of Willis of

C57BL/6 mice affects their infarct volume after cerebral-ischemia-induced injury. Studies have indicated that distal MCA occlusion (MCAO) can overcome this problem and result in a stable infarct size. In this study, we establish a two-vessel occlusion mouse model of cerebral ischemia–reperfusion through the interruption of the blood flow to the right MCA. We distally ligate the right MCA and right common carotid artery (CCA) and restore blood flow after a certain period of ischemia. This ischemia–reperfusion injury induces an infarct of stable size and a behavioral deficit. Peripheral immune cells infiltrate the ischemic brain within the 24 h infiltration period. Additionally, the neuronal loss in the cortical area is less for a longer reperfusion duration. Therefore, this two-vessel occlusion model is suitable for investigating the immune response and neuronal recovery during the reperfusion period after cerebral ischemia.

INTRODUCTION:

The cerebral ischemia–reperfusion mouse model is one of the most widely used experimental approaches for investigating the pathophysiology of ischemia-induced brain injury¹. Because cerebral ischemia–reperfusion activates the peripheral immune system, peripheral immune cells infiltrate into the ischemic brain and cause neuronal damage². Thus, a reliable and reproducible mouse model that mimics cerebral ischemia–reperfusion is required to understand the pathophysiology of stroke.

C57BL/6J (B6) mice are the most commonly used strain in stroke experiments because they can easily be genetically manipulated. Two common models of MCAO/reperfusion that mimic the condition of cerebral ischemia–reperfusion are available. The first is the intraluminal filament model of proximal MCAO, where a silicon-coated filament is employed to intravascularly occlude the blood flow in the MCA; the occluding filament is subsequently removed to restore blood flow³. A short occlusion duration results in a lesion of the subcortical region, whereas a longer occlusion duration causes infarcts in the cortical and subcortical areas. The second model is the ligation model of distal MCAO, which involves extravascular ligation of the MCA and CCA to reduce the blood flow through the MCA, after which blood flow is restored through the removal of the suture and aneurysm clip⁴. In this model, an infarct is caused in the cortical areas, and the mortality rate is low. Because the ligation of MCAO/reperfusion model requires craniectomy to expose the site of the distal MCA, the site can be easily confirmed, and examining whether the blood flow in the distal MCA is disrupted during the procedure is straightforward.

B6 mice exhibit considerable variations in the anatomy of their circle of Willis; this might affect the infarct volume following cerebral ischemia–reperfusion^{5–7}. Currently, this problem can be overcome through ligation of the distal MCA⁸. In this study, we establish a method for occluding the MCA blood flow and enabling reperfusion after a predetermined period of ischemia. Two-vessel occlusion of the cerebral ischemia–reperfusion model induces transient ischemia of the MCA territory through ligation of the right distal MCA and right CCA, with blood flow restored after a certain period of ischemia. This MCAO/reperfusion model induces an infarct of stable size, a bulk of brain-infiltrating immune cells in the ischemic brain, and a behavioral deficit after cerebral ischemia–reperfusion⁴.

PROTOCOL:

The institutional animal care and use committees of Academia Sinica and Taipei Medical University approved this protocol for the use of experimental animals.

1. MCAO/reperfusion model

1.1. Provide the mice with free access to water and chow until the surgery.

1.2. Autoclave the surgical tools and sanitize the surgery table and equipment using 70% ethanol. Wear a surgical mask and sterile gloves. Use a dry bead sterilizer to resterilize the surgical tools if multiple mouse surgeries will be conducted in one experiment.

1.3. Anesthetize an 8- to 12-week-old mouse (mass: 25–30 g) by using 0.8% chloral hydrate, via an intraperitoneal injection. Make sure the anesthetized mouse does not have a pedal reflex (as tested using a firm toe pinch) after the anesthetization.

1.4. Use vet ointment to prevent eye dryness for the mouse while it is under anesthesia.

1.5. Use a noninvasive blood pressure system to monitor the mouse's blood pressure.

1.6. Use a physiological monitoring system to monitor its rectal temperature and arterial blood gases. Maintain the body temperature at 36.5 ± 0.5 °C.

1.7. Subcutaneously inject the mouse with a prophylactic antibiotic (25 mg/kg cefazolin)⁸.

1.8. Place the mouse in the supine position on the heating pad.

1.9. Use electric clippers to expose the skin by shaving the mouse's fur on the ventral neck region, as well as in the region between the right eye and right ear.

1.10. Use tape to clear the fur from the mouse's body and disinfect the surgical site with 70% ethanol.

1.11. Use iris scissors to cut a 1 cm-long midline incision at the neck.

1.12. Use iris forceps to carefully dissect the CCA free from the vagus nerves without causing physical injury.

1.13. Use 5-0 silk sutures to isolate the CCA.

1.14. Make a 0.3 cm incision in the scalp at the midpoint between the right eye and right ear.

1.15. Use microscissors to cut the temporalis muscle to expose the zygomatic and squamosal bone.

1.16. Under a stereo dissecting microscope, use a microdrill to create a 2 mm-diameter hole directly over the right-side distal MCA.

1.17. Ligate the trunk of the right-side distal MCA using a 10-0 suture.

1.18. Occlude the right-side CCA using a nontraumatic aneurysm clip.

1.19. After either 10 or 40 min of ischemia, remove the aneurysm clips and suture to restore blood flow to the MCA and CCA.

1.20. Use a suture clip to seal the skin incision on the head.

1.21. Seal the cervical skin incisions using surgical glue⁹.

1.22. Subcutaneously inject buprenorphine (0.1 mg/kg) for pain relief⁹.

1.23. Maintain the mouse's body temperature at 36.5 ± 0.5 °C on the heating pad until it has fully recovered from the anesthesia. Do not return the animal that has undergone surgery to the company of other animals until it has fully recovered. Do not leave the animal unattended until it regains sufficient consciousness.

1.24. Place the mouse into the autoclaved cage so that it can freely access water and chow after it has fully recovered.

2. Staining with 2,3,5-triphenyltetrazolium chloride

2.1. Anesthetize the mouse with 0.8% chloral hydrate via an intraperitoneal injection.

2.2. Use operating scissors to decapitate the animal.

2.3. Expose the skull by using iris scissors to make an incision in the skin of the head.

2.4. Use operating scissors to cut the anterior of the frontal bone.

2.5. Use iris scissors to cut the skull along the sagittal suture.

2.6. Use a bone rongeur to push aside the frontal and parietal bone and expose the brain.

2.7. Use iris forceps to dissect the brain.

2.8. Use a mouse brain matrix and razor blades to obtain 2 mm coronal slices.

2.9. Stain the brain slices for 10 min at 37 °C with 2% 2,3,5-triphenyltetrazolium chloride (TTC) in 1x phosphate-buffered saline.

177
178 2.10. Rinse the brain 2x with 10% formalin.

179
180 2.11. Fix the brain in 10% formalin at room temperature for 24 h.

181 182 **3. Measurement of infarct size**

183
184 3.1. Arrange the sections on a clean plastic slide and orient the sections from rostral to caudal.

185
186 3.2. Scan the slide using a scanner. Place a metric ruler and make sure it is visible in the scanned
187 image. Flip the slide over and scan the reverse side.

188
189 3.3. Calculate the infarction area of each section using ImageJ software.

190
191 3.3.1. Open the image file and set up the scale for the image.

192
193 3.3.2. Use freehand selection to select the infarct area.

194
195 3.3.3. Use the regions of interest (ROI) manager to measure the area of interest.

196
197 3.4. Sum the infarction areas for each section and multiply the result by the section thickness to
198 estimate the total infarction volume.

199 200 **4. Statistical analysis**

201
202 4.1. Use GraphPad Prism 6 to determine the statistical significance with Student's *t*-test.

203
204 NOTE: The error bars on the bar graphs represent standard errors of the mean (SEMs).

205
206 4.2. Use G*Power 3.1 to calculate the appropriate sample size and perform a power analysis¹⁰.

207 208 **REPRESENTATIVE RESULTS:**

209 This MCAO/reperfusion procedure produced a cortical infarct in the vicinity of the right MCA and
210 caused a behavioral deficit. Different degrees of ischemia-induced infarct volume (**Figure 1A,B**)
211 and neuronal loss (**Figure 1C,D**) were created in the cerebral cortex of the right MCA area through
212 an increase in ligation duration. This MCAO/reperfusion injury decreased the animal's locomotor
213 activity at 48 h after the MCAO/reperfusion (**Figure 2**). A bulk of peripheral immune cells (CD45^{high}
214 cells) also infiltrated the ischemic brain (ipsilateral hemisphere) after the cerebral ischemia–
215 reperfusion (**Figure 3**). In addition, we compared this two-vessel occlusion model with the MCAO
216 model and found that the infarct volumes of these two models were not significantly different
217 (**Figure 4**). The mortality rate was low (<5%) in the two-vessel occlusion mouse model of cerebral
218 ischemia–reperfusion. We excluded mice from further analyses if excessive bleeding had
219 occurred during the surgery. When the surgical procedures were correctly followed, the rate of
220 animal exclusion due to excessive bleeding from craniectomy or MCA was less than 15%.

Occlusion of the right MCA or CCA alone did not cause infarction.

FIGURE AND TABLE LEGENDS:

Figure 1: Infarct volume and neuronal loss are positively correlated with the length of the vessel occlusion. (A) Representative TTC stains of brain slices from mice, 24 h after the MCAO/reperfusion. The duration of the MCAO was 10 or 40 min. Data shown are representative of three independent experiments. (B) Quantification of infarct volume. The error bars represent SEMs; $n = 8$; $*p < 0.05$. (C) The MAP2 expression in B6 brains at 24 h after MCAO/reperfusion was determined using immunohistochemistry. MAP2-negative areas are enclosed by a dashed line in the representative image of MAP2 staining of the brain section. (D) Quantification of the MAP2 negative area. $\text{MAP2-negative area (\%)} = \text{ipsilateral MAP2-negative area} / \text{contralateral hemisphere} \times 100$; $n = 3$; $*p < 0.05$.

Figure 2: Locomotor activity decreased after cerebral ischemia–reperfusion. (A) Locomotor activity was analyzed 48 h after the MCAO/reperfusion. The duration of the MCAO was 40 min. The data were recorded for 60 min in an open-field assay. Mice's tracking distances were analyzed using CleverSys TopScan 1.0. The sham control group was comprised of mice that had undergone the surgery without the occlusion of the MCA or CCA. (B) Quantification of the distance moved by the sham and the MCAO/reperfusion mice. The data are presented as mean \pm SEM; $n = 7$; $*p < 0.05$.

Figure 3: Peripheral immune cells infiltrate into the ischemic hemisphere after cerebral ischemia–reperfusion. (A) Brain-infiltrating immune cells (CD45^{high} cells) in the ipsilateral and contralateral hemisphere, at 24 h after the MCAO/reperfusion, were analyzed by flow cytometry. The isolation of brain-infiltrating immune cells has been described in a previous study⁴. The duration of the MCAO was 40 min. (B) The quantification of brain-infiltrating immune cells in the ipsilateral and contralateral hemisphere, at 24 h after the MCAO/reperfusion. The data are presented as mean \pm SEM; $n = 4$; $*p < 0.05$.

Figure 4: The infarct volume is not different between MCAO- and MCAO/reperfusion-induced injuries. (A) Representative TTC stains of brain slices from mice, 24 h after the MCAO. In the MCAO experimental group, the right MCA was permanently truncated using a vessel cauterizer, whereas the right CCA was transiently ligated for 40 min. In the MCAO/reperfusion (MCAO/Rep) experimental group, the procedure was as described in section 1 of the protocol. The duration of the MCAO was 40 min. (B) Quantification of infarct volume. The data are presented as mean \pm SEM; $n = 7$.

Table 1: Comparison of infarct volume and variability from different experiments. The infarct volume was determined at 24 h after the MCAO/reperfusion from three independent experiments. The duration of the MCAO was 40 min. SD = standard deviation; n = number of mice used per experiment.

DISCUSSION:

The MCAO/reperfusion mouse model is an animal model commonly employed to mimic transient ischemia in humans. This animal model can be applied to transgenic and knockout mice strains to investigate the pathophysiology of stroke. Several steps in the protocol are especially critical. (1) The microdrill must be carefully used when creating a hole in the skull, with inappropriate action easily causing bleeding from the MCA. (2) The MCA should not be damaged, and bleeding must be avoided before and after the ligation procedure. Damage to the MCA affects the level of reperfusion in the ischemic brain⁷. The MCA reperfusion status must be checked after the MCAO. The occlusion and restoration of blood flow to the MCA can be analyzed by using a laser Doppler. (3) The CCA should not bleed during the CCA isolation. (4) The vagus nerve must not be damaged during the CCA isolation because this could increase the infarct size and probability of mortality. (5) The body temperature of the mouse should be maintained at 36.5 ± 0.5 °C. Hyperthermia increases the infarct size and probability of mortality¹¹. Hypothermia reduces the infarct volume after cerebral ischemia¹².

The significance of this MCAO/reperfusion model is that it can create highly reproducible cortical infarcts and behavioral deficits⁴. Compared with different MCAO models, such as the hypoxic ischemic (H/I) stroke model as described in a previous study⁸, this two-vessel occlusion model induces a relatively small variability in infarct volume (the coefficient of variation ranged from 0.11–0.17) (**Table 1**). Alternative stroke models, such as the intraluminal filament model, might result in an unpredictable infarct volume because of the uncertain status of the occlusion and reperfusion condition after surgery¹³. Compared with the three-vessel MCAO model (ligation of the right MCA and right and left CCAs)¹⁴, the proposed model involves the ligation of only two vessels (the right MCA and right CCA) to achieve cerebral ischemia. Consequently, a shorter surgery time is required than in the three-vessel MCAO model. The main limitation of this MCAO/reperfusion model is that it requires craniectomy to perform MCA ligation. One study indicated that craniotomy causes transcriptional changes in the brain¹⁵. Therefore, a sham control is required to determine the effects of MCAO/reperfusion on gene expression.

Neuronal loss in the cortical area is less when a longer reperfusion duration is employed. Studies have demonstrated that the MAP2-negative area is smaller after 7 days of reperfusion, compared with 2 days of reperfusion^{4,16}. However, this recovery effect is unlikely in a brain with ischemia induced by an intraluminal monofilament model of MCAO^{17,18}. In addition, the intraluminal monofilament model of MCAO can sustain the infarct size for at least 7 days.

B6 mice have extensive collateralization between the anterior cerebral artery and the MCA¹⁹. When we permanently truncated the MCA in the ischemic brain, we found that the infarct volume was not significantly different from the mice with a reperfused MCA at 24 h after the MCAO (**Figure 4**). Therefore, we suggest that the blood flow from the anterior cerebral artery collaterals might compensate for the ischemia effects of the MCA territory when the distal MCA is permanently occluded.

In this study, the two-vessel MCAO/reperfusion model created an ischemia–reperfusion injury and caused peripheral immune cells to infiltrate into the ischemic brain. This model can be employed to investigate the interplay between the brain and the immune system. In addition, it

can be used to test potential neuroprotectants or drugs that modulate the immune response after cerebral ischemia–reperfusion.

ACKNOWLEDGMENTS:

This work was supported by the Ministry of Science and Technology, Taiwan (MOST 106-2320-B-038-024, MOST 105-2221-E-038-007-MY3, and MOST 104-2320-B-424-001) and Taipei Medical University Hospital (107TMUH-SP-01). This manuscript was edited by Wallace Academic Editing.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Woodruff, T. M. et al. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. *Molecular Neurodegeneration*. **6** (1), 11 (2011).
2. Chamorro, A. et al. The immunology of acute stroke. *Nature Reviews. Neurology*. **8** (7), 401-410 (2012).
3. Engel, O., Kolodziej, S., Dirnagl, U., Prinz, V. Modeling stroke in mice - Middle cerebral artery occlusion with the filament model. *Journal of Visualized Experiments*. (47), e2423 (2011).
4. Lee, G. A. et al. Interleukin 15 blockade protects the brain from cerebral ischemia-reperfusion injury. *Brain, Behavior, and Immunity*. **73**, 562-570 (2018).
5. Barone, F. C., Knudsen, D. J., Nelson, A. H., Feuerstein, G. Z., Willette, R. N. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. *Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism*. **13** (4), 683-692 (1993).
6. Kitagawa, K. et al. Cerebral ischemia after bilateral carotid artery occlusion and intraluminal suture occlusion in mice: evaluation of the patency of the posterior communicating artery. *Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism*. **18** (5), 570-579 (1998).
7. Wellons 3rd, J. C. et al. A comparison of strain-related susceptibility in two murine recovery models of global cerebral ischemia. *Brain Research*. **868** (1), 14-21 (2000).
8. Doyle, K. P., Fathali, N., Siddiqui, M. R., Buckwalter, M. S. Distal hypoxic stroke: a new mouse model of stroke with high throughput, low variability and a quantifiable functional deficit. *Journal of Neuroscience Methods*. **207** (1), 31-40 (2012).
9. Doyle, K. P., Buckwalter, M. S. A mouse model of permanent focal ischemia: Distal middle cerebral artery occlusion. *Methods in Molecular Biology*. **1135**, 103-110 (2014).
10. Wayman, C. et al. Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability. *Journal Of Visualized Experiments*. (108), e53106 (2016).
11. Noor, R., Wang, C. X., Shuaib, A. Effects of hyperthermia on infarct volume in focal embolic model of cerebral ischemia in rats. *Neuroscience Letters*. **349** (2), 130-132 (2003).
12. Florian, B. et al. Long-term hypothermia reduces infarct volume in aged rats after focal ischemia. *Neuroscience Letters*. **438** (2), 180-185 (2008).
13. Carmichael, S. T. Rodent models of focal stroke: size, mechanism, and purpose. *NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics*. **2** (3), 396-409 (2005).

- 353 14. Lin, T. N., Te, J., Huang, H. C., Chi, S. I., Hsu, C. Y. Prolongation and enhancement of
354 postischemic c-fos expression after fasting. *Stroke*. **28** (2), 412-418 (1997).
- 355 15. Glazier, S. S., O'Rourke, D. M., Graham, D. I., Welsh, F. A. Induction of ischemic tolerance
356 following brief focal ischemia in rat brain. *Journal of Cerebral Blood Flow and Metabolism: Official*
357 *Journal of the International Society of Cerebral Blood Flow and Metabolism*. **14** (4), 545-553
358 (1994).
- 359 16. Tachibana, M. et al. Early Reperfusion After Brain Ischemia Has Beneficial Effects Beyond
360 Rescuing Neurons. *Stroke*. **48** (8), 2222-2230 (2017).
- 361 17. Gan, Y. et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction.
362 *Proceedings of the National Academy of Sciences of the United States of America*. **111** (7), 2704-
363 2709 (2014).
- 364 18. Li, M. et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via
365 propagation of cellular immunity. *Proceedings of the National Academy of Sciences of the United*
366 *States of America*. **114** (3), E396-E405 (2017).
- 367 19. Wang, S., Zhang, H., Dai, X., Sealock, R., Faber, J. E. Genetic architecture underlying variation
368 in extent and remodeling of the collateral circulation. *Circulation Research*. **107** (4) (2010).

Fig.1




Fig.2




Fig.3




Fig.4




Table 1

Experiment	Mean Infarct volume (mm ³)	SD	N	Coefficient of variation: SD/mean
1	35.4	4.1	3	0.11
2	30	3.7	3	0.12
3	31.5	5.5	2	0.17

Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Bone rongeur	Diener		Friedman
Buprenorphine	Sigma	B-044	
Cefazolin	Sigma	1097603	
Chloral hydrate	Sigma	C8383	
Dissection microscope	Nikon	SMZ-745	
Electric clippers	Petpro		
10% formalin	Sigma	F5304	
Germinator dry bead sterilizer	Braintree Scientific		
Iris Forceps	Karl Klappenecker		10 cm
Iris Scissors	Diener		9 cm
Iris Scissors STR	Karl Klappenecker		11 cm
Microdrill	Stoelting	FOREEDOM K.1070	
Micro-scissors-Vannas	HEISS	H-4240	blade 7mm, 8 cm
Mouse brain matrix	World Precision Instruments		
Non-invasive blood pressure system	Muromachi	MK-2000ST	
Operating Scissors STR	Karl Klappenecker		14 cm
Physiological Monitoring System	Harvard Apparatus		
Razor blades	Ever-Ready		
Stoelting Rodent Warmers	Stoelting	53810	Heating pad
Suture clip	Stoelting		
Tweezers	IDEALTEK		No.3
Vetbond	3M	15672	Surgical glue
10-0 suture	UNIK	NT0410	
2,3,5-Triphenyltetrazolium chloride	Sigma	T8877	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Two-vessel occlusion mouse model of cerebral ischemia-reperfusion

Author(s):

Cheng-Yu Chen, Ray-Jade Chen, Gilbert Aaron Lee

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

612542.6 For questions, please contact us at submissions@jove.com or +1.617.945.9051.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Gilbert Aaron Lee	
Department:	Department of Medical Research	
Institution:	Taipei Medical University Hospital	
Title:	Research Fellow	
Signature:	Gilbert Aaron Lee	Date: 2018/9/9

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Dear Dr. Lee,

Your manuscript, JoVE59078R1 "Two-vessel occlusion mouse model of cerebral ischemia–reperfusion," has been editorially and peer reviewed, and the following comments need to be addressed. Note that editorial comments address both requirements for video production and formatting of the article for publication. Please track the changes within the manuscript to identify all of the edits.

After revising and uploading your submission, please also upload a separate rebuttal document that addresses each of the editorial and peer review comments individually. Please submit each figure as a vector image file to ensure high resolution throughout production: (.svg, .eps, .ai). If submitting as a .tif or .psd, please ensure that the image is 1920 x 1080 pixels or 300 dpi.

Your revision is due by Nov 30, 2018.

To submit a revision, go to the JoVE submission site and log in as an author. You will find your submission under the heading "Submission Needing Revision".

Best,

Bing Wu, Ph.D.
Review Editor
JoVE

Editorial comments:

The manuscript has been modified and the updated manuscript, 59078_R1.docx, is attached and located in your Editorial Manager account. Please use the updated version to make your revisions.

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

Reply

The manuscript has been thoroughly proofread.

2. Please specify the use of vet ointment on eyes to prevent dryness while under anesthesia.

Reply

The text has been revised in Protocol 1.4 (line 109).

3. For survival strategies, discuss post-surgical treatment of animal, including recovery conditions and treatment for post-surgical pain.

Reply

Protocol 1.23 contains the description of the recovery condition. Protocol 1.22 contains the description of postsurgical pain control.

4. Discuss maintenance of sterile conditions during survival surgery.

Reply

The maintenance of sterile conditions during survival surgery is described in Protocol 1.2 and 1.24.

5. Please specify that the animal is not left unattended until it has regained sufficient consciousness to maintain sternal recumbency.

Reply

The text has been revised in Protocol 1.23.

6. Please specify that the animal that has undergone surgery is not returned to the company of other animals until fully recovered.

Reply

The text has been revised in Protocol 1.23.

7. Figure 1A: Please add a unit.

Reply

Figure 1A has been revised.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

In this study, the authors have established a two-vessel occlusion mouse model of cerebral ischemia-reperfusion through interruption of blood flow to the right MCA. The model induces stable infarct volume and behavioral deficits, which will be beneficial to investigate the pathophysiology of cerebral ischemia-reperfusion and potential therapeutic strategies for patients with stroke. After additional editing, the manuscript may be accepted by JOVE.

Reply

Thank you for the suggestion. The manuscript has been thoroughly proofread and edited by a professional editing company.

Reviewer #3:

Manuscript Summary:

This article describes a two-vessel occlusion method in mice for cerebral ischemia reperfusion studies.

Major Concerns:

1. What is the rate of animal exclusion due to excessive bleeding from craniectomy or MCA during surgery?

Reply

If surgery procedures are correctly followed, the rate of animal exclusion due to excessive bleeding from craniectomy or MCA was less than 15%. This had been added to the Results section (line 223-224).

2. Is there any statistics supporting that the infarct area is very consistent in this method?

Reply

Thank you for the comment. We have added the statistics to show that this model induces relatively low variability of infarct area (Table 1) when compared with the H/I stroke model [1]. The text has been added to the Discussion section (line 281-283).

3. Why there is no significant difference between permanent occlusion to this reperfusion method (figure 3)? Please discuss.

Reply

We thank the reviewer for this insightful comment. B6 mice have extensive collateralization between the anterior cerebral artery (ACA) and MCA. We suggest that the blood flow from ACA collaterals might compensate for the ischemic effects of MCA territory when the distal MCA is permanently occluded. We have added this to the text in the Discussion section (line 300-305).

4. Reperfusion condition should be measured by a more accurate method such as Laser Doppler. Observation by eyes can be very subjective.

Reply

Thank you for this comment. The text has been revised in the Introduction (line 79-80) and Discussion (line 273-274).

Minor Concerns:

1. There is no direct evidence of peripheral immune cells infiltration in the ischemic brain. At least one simple IHC or H&E staining should be performed.

Reply

Thank you for the reviewer's suggestion. In our previous publication, we isolated brain-infiltrating immune cells and used flow cytometry to identify these brain-infiltrating immune cells after cerebral ischemia–reperfusion [2]. The evidence of peripheral immune cell infiltration in the ischemic brain is now presented in Figure 3. The text has been revised in the Results section (line 217-219).

1. Doyle, K.P., et al., *Distal hypoxic stroke: a new mouse model of stroke with high throughput, low variability and a quantifiable functional deficit*. J Neurosci Methods, 2012. **207**(1): p. 31-40.
2. Lee, G.A., et al., *Interleukin 15 blockade protects the brain from cerebral ischemia-reperfusion injury*. Brain Behav Immun, 2018.